Profil
Ting Jia is the founder of Octagon Capital Advisor, founded in 2019, serving as Chief Investment Officer.
Dr. Jia is currently Director at AnHeart Therapeutics LLC, Vedere Bio II, Inc., and Bluejay Therapeutics, Inc. Former positions include Managing Director at HHLR Management Pte.
Ltd. from 2015 to 2019 and Investment Analyst at BVF Partners LP from 2013 to 2015.
Education includes an undergraduate degree from Sun Yat-Sen University in 2003 and a doctorate from Weill Cornell Graduate School of Medical Sciences in 2008.
Aktive Positionen von Ting Jia
| Unternehmen | Position | Beginn |
|---|---|---|
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Develops ocular gene therapy | Direktor/Vorstandsmitglied | - |
AnHeart Therapeutics, Inc.
AnHeart Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oncology therapies | Direktor/Vorstandsmitglied | - |
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics treatments for viral and liver diseases | Direktor/Vorstandsmitglied | - |
Octagon Capital Advisor/ Private Equity
Octagon Capital Advisor/ Private Equity Investment ManagersFinance Octagon Capital invests in both public and private companies across the globe. The firm focuses on the healthcare sector. It provides financing for buyout stage capital requirements. | Gründer | 01.01.2019 |
Ehemalige bekannte Positionen von Ting Jia
| Unternehmen | Position | Ende |
|---|---|---|
HHLR Management Pte Ltd.
HHLR Management Pte Ltd. Investment ManagersFinance HHLR is a long-term investor that invests in high-quality businesses across Asia and the world. | Private Equity Investor | 31.12.2019 |
BVF Partners LP
BVF Partners LP Investment ManagersFinance BVF generally pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The focus of the BVF strategy is on fundamental, bottom-up analysis of individual issuers based on the theory that market mispricing exist because market prices do not incorporate all knowable economic and other relevant data. | Corporate Officer/Principal | 01.01.2015 |
Ausbildung von Ting Jia
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
BVF Partners LP
BVF Partners LP Investment ManagersFinance BVF generally pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The focus of the BVF strategy is on fundamental, bottom-up analysis of individual issuers based on the theory that market mispricing exist because market prices do not incorporate all knowable economic and other relevant data. | Finance |
Sun Yat-Sen University
Sun Yat-Sen University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Weill Cornell Graduate School of Medical Sciences
Weill Cornell Graduate School of Medical Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
HHLR Management Pte Ltd.
HHLR Management Pte Ltd. Investment ManagersFinance HHLR is a long-term investor that invests in high-quality businesses across Asia and the world. | Finance |
AnHeart Therapeutics, Inc.
AnHeart Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oncology therapies | Health Technology |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Develops ocular gene therapy | Commercial Services |
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics treatments for viral and liver diseases | Health Technology |
Octagon Capital Advisor/ Private Equity
Octagon Capital Advisor/ Private Equity Investment ManagersFinance Octagon Capital invests in both public and private companies across the globe. The firm focuses on the healthcare sector. It provides financing for buyout stage capital requirements. | Finance |
















